Login / Signup

Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.

Kelly M HotchkissJohn H Sampson
Published in: Journal of neuro-oncology (2020)
The different levels of lymphopenia and tumor eradication discussed in this review suggest possible beneficial pairings between immunotherapy and TMZ treatment. Treatments resulting in profound lymphopenia will allow for expansion of vaccine specific T cells or of CAT T cells. Clinical and preclinical studies are currently comparing different combinations of TMZ and immunotherapy timing to treat GBM through a balance between tumor killing and immune cell expansion. More frequent immune monitoring time points in ongoing clinical trials are crucial for further development of these combinations.
Keyphrases
  • clinical trial
  • intellectual disability
  • randomized controlled trial
  • stem cells
  • cell therapy